{
  "patient_id": "marcus_b",
  "extraction_metadata": {
    "extracted_from": [
      "01_Prior_Auth_Request_Form.pdf",
      "02_Laboratory_Results.pdf",
      "03_PET_CT_Report.pdf",
      "04_Clinical_Summary.pdf"
    ],
    "extraction_date": "2026-02-05",
    "extraction_method": "clinical_document_extraction"
  },

  "demographics": {
    "first_name": "Marcus",
    "last_name": "Bell",
    "date_of_birth": "1978-08-23",
    "age": 47,
    "gender": "Male",
    "ethnicity": "African American",
    "address": {
      "street": "2145 Peachtree Road NE, Unit 8",
      "city": "Atlanta",
      "state": "GA",
      "zip": "30309"
    },
    "phone": "404-555-0291",
    "mrn": "MARCUS_B",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "insurance": {
    "primary": {
      "payer_name": "BCBS",
      "payer_id": "BCBS_FEP",
      "plan_name": "Blue Cross Blue Shield Federal Employee Program",
      "plan_type": "PPO",
      "member_id": "FEP678123945",
      "group_number": "FEP-STANDARD-2025",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  },

  "prescriber": {
    "name": "Dr. Nadine Okafor",
    "credentials": "MD, PhD",
    "npi": "1298745632",
    "specialty": "Hematology-Oncology",
    "subspecialty": "Lymphoma",
    "practice_name": "Winship Cancer Institute of Emory University",
    "address": {
      "street": "1365 Clifton Road NE",
      "city": "Atlanta",
      "state": "GA",
      "zip": "30322"
    },
    "phone": "404-555-0700",
    "fax": "404-555-0701",
    "rems_certified_facility": true,
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "medication_request": {
    "medication_name": "Lisocabtagene maraleucel",
    "brand_name": "Breyanzi",
    "j_code": "Q2054",
    "dose": "Single infusion, patient-specific dose",
    "route": "Intravenous infusion",
    "frequency": {
      "regimen": "Single dose — lymphodepleting chemotherapy followed by CAR-T infusion"
    },
    "duration_requested": "One-time infusion authorization",
    "quantity_requested": "1 infusion",
    "site_of_care": "Certified REMS treatment center",
    "start_date_requested": "2026-04-01",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "diagnoses": [
    {
      "rank": "primary",
      "icd10_code": "C83.10",
      "description": "Mantle cell lymphoma, unspecified site",
      "status": "active",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  ],

  "disease_activity": {
    "assessment_date": "2026-01-28",
    "ann_arbor_stage": "IVA",
    "ecog_performance_status": 1,
    "mipi_score": 6.2,
    "mipi_risk_category": "High",
    "disease_status": "relapsed_refractory",
    "lines_of_therapy_completed": 3,
    "blastoid_variant": false,
    "source_documents": ["01_Prior_Auth_Request_Form.pdf", "04_Clinical_Summary.pdf"]
  },

  "clinical_history": {
    "chief_complaint": "Relapsed mantle cell lymphoma refractory to BTK inhibitor therapy, requesting CAR-T cell therapy",
    "history_of_present_illness": "47-year-old African American male with relapsed/refractory mantle cell lymphoma diagnosed January 2023. Initially presented with generalized lymphadenopathy, splenomegaly, and GI involvement. First-line R-CHOP/R-DHAP followed by autologous stem cell transplant (ASCT) — achieved complete response lasting 13 months. Relapsed November 2024 with nodal and extranodal disease. Second-line ibrutinib (BTK inhibitor) for 8 months — initial partial response but then progressed with rising LDH and new splenic lesions. Third-line lenalidomide/rituximab x4 cycles with progressive disease. Now referred for CAR-T cell therapy. CD19 positivity confirmed on most recent biopsy.",
    "prior_car_t_therapy": false,
    "prior_gene_therapy": false,
    "source_document": "04_Clinical_Summary.pdf"
  },

  "prior_treatments": [
    {
      "medication_name": "R-CHOP / R-DHAP + ASCT",
      "drug_class": "Intensive chemoimmunotherapy + autologous transplant",
      "components": ["Rituximab (anti-CD20)", "Cyclophosphamide", "Doxorubicin (anthracycline)", "Vincristine", "Prednisone", "Dexamethasone", "Cytarabine", "Cisplatin"],
      "line": 1,
      "start_date": "2023-02-15",
      "end_date": "2023-09-30",
      "outcome": "complete_response_then_relapsed",
      "outcome_description": "Complete response after ASCT. Relapsed at 13 months (November 2024).",
      "contains_anti_cd20": true,
      "contains_anthracycline": true,
      "source_document": "04_Clinical_Summary.pdf"
    },
    {
      "medication_name": "Ibrutinib",
      "drug_class": "BTK inhibitor",
      "dose": "560 mg daily",
      "line": 2,
      "start_date": "2024-12-01",
      "end_date": "2025-07-31",
      "duration_months": 8,
      "outcome": "partial_response_then_progressed",
      "outcome_description": "Initial partial response (40% nodal reduction). Progressed at 8 months with rising LDH and new splenic lesions. Meets definition of BTK inhibitor failure.",
      "is_btk_inhibitor": true,
      "btk_inhibitor_tried_and_failed": true,
      "source_document": "04_Clinical_Summary.pdf"
    },
    {
      "medication_name": "Lenalidomide + Rituximab (R2)",
      "drug_class": "Immunomodulatory agent + anti-CD20",
      "line": 3,
      "start_date": "2025-09-01",
      "end_date": "2026-01-15",
      "cycles_completed": 4,
      "outcome": "progressive_disease",
      "outcome_description": "Progressive disease on restaging PET/CT. New hepatic and peritoneal nodal disease.",
      "contains_anti_cd20": true,
      "source_document": "04_Clinical_Summary.pdf"
    }
  ],

  "laboratory_results": {
    "collection_date": "2026-01-25",
    "source_document": "02_Laboratory_Results.pdf",
    "panels": {
      "cbc": {
        "panel_name": "Complete Blood Count",
        "results": [
          {"test": "WBC", "value": 8.4, "unit": "x10^9/L", "reference_range": "4.5-11.0", "flag": null},
          {"test": "Hemoglobin", "value": 12.6, "unit": "g/dL", "reference_range": "13.5-17.5", "flag": "L"},
          {"test": "Platelets", "value": 178, "unit": "x10^9/L", "reference_range": "150-400", "flag": null},
          {"test": "ANC", "value": 5.1, "unit": "x10^9/L", "reference_range": "1.5-8.0", "flag": null}
        ]
      },
      "cmp": {
        "panel_name": "Comprehensive Metabolic Panel",
        "results": [
          {"test": "LDH", "value": 345, "unit": "U/L", "reference_range": "140-280", "flag": "H"},
          {"test": "Creatinine", "value": 1.0, "unit": "mg/dL", "reference_range": "0.7-1.3", "flag": null},
          {"test": "AST", "value": 28, "unit": "U/L", "reference_range": "10-40", "flag": null},
          {"test": "ALT", "value": 32, "unit": "U/L", "reference_range": "7-56", "flag": null},
          {"test": "Total Bilirubin", "value": 0.9, "unit": "mg/dL", "reference_range": "0.1-1.2", "flag": null}
        ]
      },
      "viral_screening": {
        "panel_name": "Pre-CAR-T Viral Screening",
        "results": [
          {"test": "HBsAg", "value": "Negative", "flag": null},
          {"test": "Anti-HBc", "value": "Negative", "flag": null},
          {"test": "HCV Antibody", "value": "Negative", "flag": null},
          {"test": "HIV 1/2 Ab/Ag", "value": "Negative", "flag": null}
        ]
      }
    }
  },

  "procedures": {
    "pet_ct": {
      "procedure_name": "PET/CT Restaging",
      "procedure_date": "2026-01-20",
      "findings": "Progressive disease with new hepatic lesions (largest 2.8 cm, SUV 14.2) and peritoneal nodal disease. Persistent splenomegaly (18 cm). Multiple FDG-avid nodes above and below diaphragm. Deauville 5.",
      "source_document": "03_PET_CT_Report.pdf"
    }
  },

  "organ_function_assessment": {
    "cardiac": {"lvef": "60%", "method": "Echocardiogram", "status": "adequate"},
    "pulmonary": {"status": "adequate"},
    "hepatic": {"status": "adequate"},
    "renal": {"status": "adequate", "creatinine_clearance": "95 mL/min"}
  },

  "pa_criteria_assessment": {
    "diagnosis_confirmed": {
      "met": true,
      "evidence": "Mantle cell lymphoma confirmed (ICD-10 C83.10). CD19-positive on immunohistochemistry."
    },
    "mcl_indication_covered": {
      "met_under_2024": false,
      "met_under_2025": true,
      "evidence": "MCL was NOT an approved indication under the 2024 Breyanzi policy — only LBCL subtypes were covered. The 2025 policy ADDED MCL as a new indication (DIAG_MCL criterion) along with specific step therapy (STEP_MCL requiring 2+ prior lines including BTK inhibitor)."
    },
    "age_requirement": {
      "met": true,
      "evidence": "Patient is 47 years old (>=18)"
    },
    "prior_btk_inhibitor": {
      "met": true,
      "evidence": "Received ibrutinib (BTK inhibitor) for 8 months with initial response then progression. Meets MCL_BTK_REQ under 2025 policy."
    },
    "lines_of_therapy": {
      "met": true,
      "evidence": "3 prior lines of systemic therapy (exceeds MCL_2_LINES requirement of 2+)"
    },
    "prior_anti_cd20": {
      "met": true,
      "evidence": "Rituximab in lines 1 and 3"
    },
    "prior_anthracycline": {
      "met": true,
      "evidence": "Doxorubicin in R-CHOP (line 1)"
    },
    "rems_facility": {
      "met": true,
      "evidence": "Winship Cancer Institute is a certified REMS treatment center"
    },
    "no_prior_gene_therapy": {"met": true},
    "no_active_infection": {"met": true},
    "adequate_organ_function": {"met": true},
    "no_cns_lymphoma": {"met": true}
  },

  "overall_pa_readiness": {
    "status": "POLICY_VERSION_DEPENDENT",
    "blocking_issues_2024": [
      "MCL is NOT a covered indication under the 2024 Breyanzi policy"
    ],
    "blocking_issues_2025": [],
    "criteria_met_count_2024": "N/A — indication not covered",
    "criteria_met_count_2025": 11,
    "criteria_total_count_2025": 11,
    "policy_version_impact": {
      "qualifies_under_2024": false,
      "qualifies_under_2025": true,
      "change_causing_new_eligibility": "DIAG_MCL + STEP_MCL + MCL_BTK_REQ — 2025 policy expanded Breyanzi coverage to include Mantle Cell Lymphoma. Marcus meets all new MCL-specific requirements: 3 prior lines (>=2 required), tried and failed a BTK inhibitor (ibrutinib), and has prior anti-CD20 + anthracycline exposure.",
      "clinical_significance": "This case demonstrates the beneficial expansion of the 2025 policy. Under 2024, MCL patients had no access to Breyanzi regardless of clinical need. The 2025 update, aligned with the FDA's expanded indication, now covers MCL patients who have failed BTK inhibitor therapy — a population with very limited remaining options.",
      "impact_notes": "Marcus would have been denied under 2024 solely because MCL was not a covered indication. Under 2025, he meets every criterion. This is one of the most impactful positive changes in the policy update."
    }
  }
}
